Gueli Alletti Salvatore, Perrone Emanuele, Fedele Camilla, Cianci Stefano, Pasciuto Tina, Chiantera Vito, Uccella Stefano, Ercoli Alfredo, Vizzielli Giuseppe, Fagotti Anna, Gallotta Valerio, Cosentino Francesco, Costantini Barbara, Restaino Stefano, Monterossi Giorgia, Rosati Andrea, Turco Luigi Carlo, Capozzi Vito Andrea, Fanfani Francesco, Scambia Giovanni
Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Institute of Obstetrics and Gynecology, Universita' Cattolica del Sacro Cuore, Rome, Italy.
Front Oncol. 2021 Sep 10;11:720894. doi: 10.3389/fonc.2021.720894. eCollection 2021.
This prospective randomized trial aimed to assess the impact of the uterine manipulator in terms of lymph vascular space invasion (LVSI) in patients undergoing minimally invasive staging for early-stage endometrial cancer.
In this multicentric randomized trial, enrolled patients were randomly allocated in two groups according to the no use (arm A) or the use (arm B) of the uterine manipulator. Inclusion criteria were G1-G2 early-stage endometrial cancer at preoperative evaluation. The variables collected included baseline demographic characteristics, perioperative data, final pathology report, adjuvant treatment, and follow-up.
In the study, 154 patients (76 in arm A and 78 in arm B) were finally included. No significant differences were recorded regarding the baseline characteristics. A statistically significant difference was found in operative time for the laparoscopic staging (p=0.005), while no differences were reported for the robotic procedures (p=0.419). The estimated blood loss was significantly lower in arm A (p=0.030). No statistically significant differences were recorded between the two study groups in terms of peritoneal cytology, LVSI (p=0.501), and pattern of LVSI (p=0.790). No differences were detected in terms of overall survival and disease-free survival (p=0.996 and p=0.480, respectively). Similarly, no differences were recorded in the number of recurrences, 6 (7.9%) in arm A and 4 (5.2%) in arm B (p=0.486). The use of the uterine manipulator had no impact on DFS both at univariable and multivariable analyses.
The intrauterine manipulator does not affect the LVSI in early-stage endometrial cancer patients undergoing laparoscopic/robotic staging.
https://clinicaltrials.gov, identifier (NCT: 02762214).
这项前瞻性随机试验旨在评估子宫操纵器对早期子宫内膜癌微创分期患者淋巴血管间隙浸润(LVSI)的影响。
在这项多中心随机试验中,根据是否使用子宫操纵器(A组不使用,B组使用)将入选患者随机分为两组。纳入标准为术前评估为G1-G2期早期子宫内膜癌。收集的变量包括基线人口统计学特征、围手术期数据、最终病理报告、辅助治疗和随访情况。
该研究最终纳入154例患者(A组76例,B组78例)。两组基线特征无显著差异。腹腔镜分期的手术时间存在统计学显著差异(p=0.005),而机器人手术则无差异(p=0.419)。A组估计失血量显著更低(p=0.030)。两组在腹膜细胞学、LVSI(p=0.501)和LVSI模式(p=0.790)方面无统计学显著差异。总生存期和无病生存期方面也无差异(分别为p=0.996和p=0.480)。同样,复发次数也无差异,A组6例(7.9%),B组4例(5.2%)(p=0.486)。单变量和多变量分析中,子宫操纵器的使用对无病生存期均无影响。
子宫内操纵器对接受腹腔镜/机器人分期的早期子宫内膜癌患者的LVSI无影响。